Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

Abstract: According to one embodiment, a controller includes a first interface, a second interface, a virtual register table, a memory management unit and a calculation processing unit. The first interface receives an I/O command from a host. The second interface transmits and receives first host data to and from a storage. The virtual register table has a virtual address specified by a page number assigned to a page in which data to be used to process a calculation instruction is stored and a page offset, and a data size of the data. The memory management unit stores, into a memory, the copy of the first host data, and updates the virtual register table. The calculation processing unit processes the calculation instruction by referring to the virtual register table.

Abstract: A thermal management system includes a circulation channel that connects a motor cooler, outside air heat exchanger, and a heater, a switching valve, and a controller. In a heating mode of operating the heater, the controller sets the switching valve in the first valve position when the motor temperature is lower than a motor temperature threshold value, and sets the switching valve in the second valve position when the motor temperature is higher than the motor temperature threshold value. When a load or a load predicted value of the motor exceeds a load threshold value, the controller holds the switching valve in the second valve position during a predetermined holding time.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies and combination pharmaceuticals employing those modulators, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: The present disclosure provides a technique related to a cooler including a main channel in which an object to be cooled is attached to an upper surface thereof, and a structure which prevents air bubbles from entering the main channel. A cooler for cooling an object may include: a main channel in which coolant flows, wherein the object is attached to an upper surface of the main channel; and a sub channel bypassing the main channel, wherein a ceiling of the sub channel is higher than a ceiling of the main channel at a branch point between the main channel and the sub channel. Air bubbles trapped in the coolant flow into the sub channel having a higher ceiling height, thus they do not enter the main channel.

Abstract: A heat management system disclosed herein is used for an electric vehicle. The heat management system may include an oil cooler, an oil pump, a converter cooler, a first heat exchanger, a second heat exchanger, a first channel, a second channel, a channel valve, a bypass channel, and a controller. The channel valve may be configured to select a first valve position and a second valve position. The bypass channel may be configured to allow the first heat medium to bypass the first heat exchanger and circulate between the oil cooler and the converter cooler when the second valve position is selected. The controller may be configured to control the channel valve such that the channel valve selects the first valve position and activate the oil pump in response to the temperature of the first heat medium in the first channel becoming higher than a predetermined upper limit temperature.

Abstract: A heat management system disclosed herein is used for an electric vehicle. The heat management system may comprise an oil cooler, an oil pump, a converter cooler, a first heat exchanger, a second heat exchanger, a first channel, a second channel, a channel valve, a bypass channel, and a controller. While executing the heat pump mode, the controller may be configured to periodically execute an operation of: switching the channel valve from the second valve position to the first valve position and activating the oil pump; and returning the channel valve from the first valve position to the second valve position and inactivating the oil pump in response to a predetermined time having passed.

Abstract: Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Abstract: A thermal management system includes a circulation channel that connects a motor cooler, outside air heat exchanger, and a heater, a switching valve, and a controller. In a heating mode of operating the heater, the controller sets the switching valve in the first valve position when the motor temperature is lower than a motor temperature threshold value, and sets the switching valve in the second valve position when the motor temperature is higher than the motor temperature threshold value. When a load or a load predicted value of the motor exceeds a load threshold value, the controller holds the switching valve in the second valve position during a predetermined holding time.

Abstract: A heat management system disclosed herein is used for a vehicle. The heat management system may include an electric device, a first heat exchanger, a second heat exchanger, a first channel, a second channel, a first pump, a second pump, a first channel valve, a second channel valve, a bypass channel, and a controller. The controller may be configured to, when one of the first pump and the second pump operates abnormally, control the first channel valve and the second channel valve such that the flow of the first heat medium from both of the first channel and the second channel to the first heat exchanger is allowed and activate the other of the first pump and the second pump.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.